ClinicalTrials.gg
Status unknownNCT04486651Updated Jan 28, 2021

HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

A Phase 3 interventional study of Irinotecan Hydrochloride Injection and HX008 in Stomach Cancer, sponsored by Taizhou Hanzhong biomedical co. LTD. Status unknown at 64 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Taizhou Hanzhong biomedical co. LTD · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
560
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,184 studies in Stomach Neoplasms with a site in China — 481 open to participants now, 557 under way, 50 of them phase 3. Stomach Neoplasms · China.

Planned enrollment
112th of 881
560 · median 87
Started
2020
with 66 others
Phase 3
122 of 1,184
33 open now
Registered
454th of 1,184
by date

Among the 1,184 studies in Stomach Neoplasms with a site in China, this one is the 112th largest by planned enrollment of the 881 interventional ones that give a count, is one of 67 that started in 2020, is one of 122 in phase 3, and was the 454th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

481 of the 1,184 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

476 more — sign in →

All 481 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,184 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blinded, multicenter study to evaluate the efficacy and safety of HX008 injection combined with irinotecan versus placebo combined with irinotecan as second-line therapy in patients with adcanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have had tumor progression after first-line treatment with platinum and/or fluropyrimidine therapy.

03

Conditions studied

  • Stomach Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Understood and signed an form.
  • Age ≥ 18 and ≤ 75 years old, male or female.
  • Has - or cytologically-confirmed diagnosis of locally advanced unresectable or adenocarcinoma of stomach or the esophagogastric junction (GEJ).
  • Has experienced documented objective radiographic or clinical disease progression during or after therapy containing platinum and/or fluoropyrimidine therapy.
  • Willing to provide tissue for biomarker analysis.
  • Has a performance status of 0 or 1 on the (ECOG) Performance Score.
  • ≥ 3 months.
  • Has adequate organ function.
  • Female participants of should have a negative pregnancy within 72 hours before the randomization. Male and female participants should agree to use an adequate method of during the experiment and 1 year after the last administration of the test drugs.

Exclusion criteria

Exclusion Criteria:

  • Has squamous cell or undifferentiated gastric cancer.
  • Diagnosed additional maliganancy within 3 years prior to randomization with the expection of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin,curatively resected in situ cervival or non-muscle invasive bladder cancers.
  • Has had a prior anti-cancer monoclonal antibody within 4 weeks prior to the first dose of trial treatment or who has not recovered (≤ Grade 1 or at Baseline) from AEs due to agents administered more than 4 weeks earlier.
  • Has had prior chemotherapy,radiation therapy or targeted small molecular therapy within 2 weeks prior to the first dose of trial treatment or who has not recovered (≤ Grade 1 or at Baseline) from AEs due to a previously administrated agent.
  • Has received prior therapy with an , or anti-PD-L1, or anti-CTLA-4 agents.
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  • Has uncontrolled ascites, pleural effusion, or pericardial effusion.
  • Has active disease that has required systemic treatment in past 2 years.
  • Has received a major surgery within 4 weeks prior to randomization.
  • Has received system treatment with (dose >10mg/day prednison or other therapeutic hormones) within 2 weeks prior to the first dose of trial treatment.
  • Has incomplete intestinal obstruction, active gastrointestinal hemorrhage and perforation.
  • Has a history of non-infectious pneumonitis that required steriods or has current pneumonitis.
  • Has any serious and/or uncontrolled disease.
  • Has active viral infection.
  • Has received a within 30 days prior to the first dose of trial treatment.
  • Has participated in other anticancer drug clinical trials within 4 weeks.
  • According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
560 participants (estimated)

Study arms

  • Experimental
    HX008 plus Irinotecan

    Participants recieve HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus irinotecan 160 mg/m², IV, Q2W.

    Drug: Irinotecan Hydrochloride Injection · Drug: HX008

  • Placebo comparator
    Placebo plus Irinotecan

    Participants recieve placebo intravenous (IV) every 3 weeks (Q3W) plus irinotecan 160 mg/m², IV, Q2W.

    Drug: Irinotecan Hydrochloride Injection · Drug: Placebo

Interventions

  • 160 mg/m² administered as IV infusion on Day 1 of each 14-day cycle.

  • DrugHX008

    200 mg administered as IV infusion on Day 1 of each 21-day cycle.

  • DrugPlacebo

    Administered as IV infusion on Day 1 of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in All Participants

    OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. OS is reported here for all participants in the experimental arm and placebo comparator arm.

    Time frame: Up to approximately 36 months

  2. Overall Survival (OS) in Participants With PD-L1 CPS≥1

    OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. OS is reported here for all participants in the experimental arm and placebo comparator arm with PD-L1 CPS≥1.

    Time frame: Up to approximately 36 months

Secondary outcomes

  1. Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    PFS was defined as the time from randomization to the first documented disease progression per RECIST 1.1 assessed by investigators or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 36 months

  2. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    ORR was defined as the percentage of participants who have a complete response (CR) or a partial response (PR), per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.

    Time frame: Up to approximately 36 months

  3. Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    DCR was defined as the percentage of participants who have a CR or a PR or a stable disease (SD), per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.

    Time frame: Up to approximately 36 months

  4. Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    DOR was defined as the time from the first documented evidence of a response of CR or PR, per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.

    Time frame: Up to approximately 36 months

07

Study locations

52 of 64 sites recruiting
  • Anhui Provincial Cancer Hospital
    Hefei, Anhui 230000, China
    Recruiting
    • Yifu He · Contact
  • Anhui Provincial Hospital
    Hefei, Anhui 230001, China
    Recruiting
    • Yueyin Pan · Contact
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
    Recruiting
    • Zhendong Chen · Contact
  • Beijing ChaoYang Hospital, Capital Medical University
    Beijing, Beijing 100020, China
    Recruiting
    • Guangyu An · Contact
  • Cancer Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
    Recruiting
  • Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
    Recruiting
    • Lin Zhao · Contact
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100050, China
    Recruiting
    • Bangwei Cao · Contact
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
    Recruiting
    • Baoshan Cao · Contact
  • Peking University Internationale Hospital
    Beijing, Beijing 102206, China
    Recruiting
    • Jun Liang · Contact
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing 400030, China
    Recruiting
    • Weiqing Chen · Contact
  • Fujian Cancer Hospital
    Xiamen, Fujian 350000, China
    Recruiting
    • Rongbo Lin · Contact
  • Gansu Wuwei Tumor Hospital
    Wuwei, Gansu 350000, China
    Recruiting
    • Rongbo Lin · Contact
  • Affiliated Cancer Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510095, China
    Not yet recruiting
    • Chuan Jin · Contact
  • Zhongshan People's Hospital
    Guangzhou, Guangdong 528403, China
    Not yet recruiting
    • Jianjun Xiao · Contact
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518035, China
    Recruiting
    • Shubin Wang · Contact
  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
    Shenzhen, Guangdong 518117, China
    Recruiting
    • Chunxia Du · Contact
  • Guangxi Medical University Cancer Hospital
    Naning, Guangxi 530021, China
    Recruiting
    • Zhihui Liu · Contact
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangzhou 510080, China
    Not yet recruiting
    • Sheng Ye · Contact
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050011, China
    Recruiting
    • Shengmian Li · Contact
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050051, China
    Recruiting
    • Na Li · Contact
  • Affiliated Hospital of Hebei University
    Shijiazhuang, Hebei 071000, China
    Recruiting
    • Aimin Zang · Contact
  • The affiliated Cancer Hospital of Harbin Medical University
    Harbin, Heilongjiang 150081, China
    Recruiting
    • Yuxian Bai · Contact
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
    Recruiting
    • Suxia Luo · Contact
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Recruiting
    • Qingxia Fan · Contact
  • The First Affiliated Hospital of Henan Science&Technology University
    Zhengzhou, Henan 471000, China
    Recruiting
    • Xinshuai Wang · Contact
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 540003, China
    Recruiting
    • Shundong Cang · Contact
  • The Second Xiangya Hospital of Cancer South University
    Changsha, Hunan 410000, China
    Recruiting
    • Xianling Liu · Contact
  • Xiangya Hospital, Central South University
    Changsha, Hunan 410000, China
    Not yet recruiting
    • Shan Zeng · Contact
  • Hunan Cancer Hospital
    Changsha, Hunan 410200, China
    Recruiting
    • Xianli Yin · Contact
  • The Affiliated People's Hospital of Inner Mongolia Medical University
    Huhhot, Inner Mongolia 010000, China
    Recruiting
    • Zhenping Wen · Contact
  • Changzhou Cancer Hospital
    Changzhou, Jiangsu 213000, China
    Recruiting
    • Yang Ling · Contact
  • Jiangsu Provincial Hospital
    Nanjing, Jiangsu 210000, China
    Recruiting
    • Lingjun Zhu · Contact
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210009, China
    Recruiting
    • Yang Yang · Contact
  • Zhongda Hospital Southeast Universtiy
    Nanjing, Jiangsu 210009, China
    Not yet recruiting
    • Cailian Wang · Contact
  • Nantong Tumor Hospital
    Nantong, Jiangsu 226006, China
    Recruiting
    • Lei Yang · Contact
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215000, China
    Recruiting
    • Zhixiang Zhuang · Contact
  • Xuzhou Central Hospital
    Xuzhou, Jiangsu 221009, China
    Recruiting
    • Yuan Yuan · Contact
  • Yangzhou FIrst People's Hospital
    Yangzhou, Jiangsu 225000, China
    Recruiting
    • Jiandong Tong · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Xiaojun Xiang · Contact
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi 330029, China
    Recruiting
    • Yiye Wan · Contact
  • Jilin Cancer Hospital
    Changchun, Jilin 130000, China
    Recruiting
    • Ying Cheng · Contact
  • The First Hospital of Jilin University
    Changchun, Jilin 130000, China
    Not yet recruiting
    • Wei Li · Contact
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
    Not yet recruiting
    • Yunpeng Liu · Contact
  • Liaoning Cancer Hospital
    Shenyang, Liaoning 110042, China
    Recruiting
    • Jingdong Zhang · Contact
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750001, China
    Recruiting
    • Ping Chen · Contact
  • Shandong Provincial Hospital
    Jinan, Shandong 250000, China
    Recruiting
    • Weibo Wang · Contact
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
    Recruiting
    • Bo Liu · Contact
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266000, China
    Recruiting
    • Jing Lv · Contact
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264000, China
    Not yet recruiting
    • Ping Sun · Contact
  • Shanghai General Hospital
    Shanghai, Shanghai 200000, China
    Recruiting
    • Hongxia Wang · Contact
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai 200233, China
    Not yet recruiting
    • Zan Shen · Contact
  • Shanxi Cancer Hospital
    Taiyuan, Shanxi 030013, China
    Recruiting
    • Lu Wen · Contact
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 710061, China
    Not yet recruiting
    • Enxiao Li · Contact
  • Sichuan Cancer Hospital
    Chengdu, Sichuan 610041, China
    Recruiting
    • Jin Lu · Contact
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
    Recruiting
    • Diansheng Zhong · Contact
  • Hubei Cancer Hospital
    Hubei, Wuhan 430000, China
    Recruiting
    • Xinjun Liang · Contact
  • The First Affiliated Hospital of Xinjiang Medical University
    Urumqi, Xinjiang 830000, China
    Recruiting
    • Wenran Wang · Contact
  • Xinjiang Medical University Cancer Hospital
    Urumqi, Xinjiang 830000, China
    Not yet recruiting
    • Yong Tang · Contact
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650100, China
    Not yet recruiting
    • Qing Bi · Contact
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
    Recruiting
    • Yi Zheng · Contact
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang 310014, China
    Recruiting
    • Liqin Lu · Contact
  • Sir Run Run Shaw Hospital, Medical School of Zhejiang University
    Hangzhou, Zhejiang 310016, China
    Recruiting
    • Hongming Pan · Contact
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
    Recruiting
    • Haijun Zhong · Contact
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
    Recruiting
    • Zhiming Huang · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Aug 2023, 34 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's planned 34 months is below that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2020
First posted
Jul 24, 2020
StartActual
Sep 16, 2020
Primary completionEst.
Aug 10, 2023
CompletionEst.
Aug 10, 2023
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04486651
Lead sponsor
Taizhou Hanzhong biomedical co. LTD
Responsible party
Sponsor
First posted
Jul 24, 2020
Start date
Sep 16, 2020
Primary completion
Aug 10, 2023 (estimated)
Completion
Aug 10, 2023 (estimated)
Last update
Jan 28, 2021

Study contacts

Jing Huang, MD
Contact
huangjingwg@163.com
010-87788113

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pucotenlimab

Start the discussion